Disclosed are novel A.sub.2B adenosine receptor antagonists having the structure of Formula I or Formula II ##STR00001## The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.